Neuroscience drug discovery is entering a new phase of acceleration, driven by advances in artificial intelligence, biomarker science, and brain-targeted drug delivery. These technologies are…
February 19, 2026
Eli Lilly and Company (NYSE: LLY) has reported encouraging results from its Phase 3b clinical trial evaluating a combination of Taltz and Zepbound. Notably, the…
February 17, 2026
Ocular Therapeutix Stock Plummets Following Wet AMD Trial Results
Ocular Therapeutix (NASDAQ: OCUL) experienced a sharp 35% drop in its stock price on Tuesday, despite reporting seemingly positive outcomes from its Phase 3 superiority…
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a biopharmaceutical company focused on first-in-class critical care products, announced its first reported revenue after the successful launch of LYMPHIR™….
February 13, 2026
Immunic Secures $400 Million Financing to Propel Multiple Sclerosis Programs and Commercial Transition
Immunic, Inc. (NASDAQ:IMUX) shares surged 20% in Friday morning trading following the announcement of a significant oversubscribed private placement. This financing deal positions the company…
February 12, 2026
Madrigal Signals MASH Monopoly with $4.4 Billion RNAi Pact
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is aggressively expanding its therapeutic footprint within the multi-billion dollar liver disease market. The company recently finalized a strategic licensing…
Moderna, Inc. (NASDAQ: MRNA) tumbled sharply this week after the U.S. Food and Drug Administration (FDA) announced it would not review the company’s application for…
Citius Oncology (NASDAQ: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (NASDAQ: CTXR), has signed an exclusive European Union distribution agreement for its oncology immunotherapy LYMPHIR™…
Merck & Co. (NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX for the treatment of certain…
Personalis Inc. (NASDAQ: PSNL) jumped 9.3% on Tuesday after the company announced that Medicare approved coverage for its NeXT Personal molecular residual disease (MRD) test…
Novo Nordisk (NYSE: NVO) reported new late-stage clinical results showing its next-generation obesity therapy CagriSema outperformed Wegovy in a head-to-head study, strengthening the company’s position…
February 10, 2026
Evommune Stock Skyrockets Following Positive Phase 2a Trial Results for Eczema Drug
In a significant development for the biotechnology sector, Evommune Inc. (NYSE:EVMN) saw its stock soar by an impressive 64% after announcing positive top-line results from…